Valuation: DexCom, Inc.

Market Cap 27.61B 24.27B 22.59B 20.75B 38.96B 2,647B 39.47B 269B 105B 1,307B 104B 101B 4,518B P/E 2026 *
29.1x
P/E 2027 * 24.3x
Enterprise Value 27.18B 23.89B 22.24B 20.42B 38.35B 2,606B 38.86B 264B 103B 1,287B 102B 99.82B 4,448B EV / Sales 2026 *
5.2x
EV / Sales 2027 * 4.52x
Free-Float
93.35%
Yield 2026 *
-
Yield 2027 * -
1 day+3.04%
1 week-6.29%
Current month-0.32%
1 month-0.32%
3 months+15.93%
6 months+1.72%
Current year+9.14%
1 week 62
Extreme 62
65.8
1 month 62
Extreme 62
68.6
Current year 48.8
Extreme 48.8
68.6
1 year 47
Extreme 47
77.99
3 years 47
Extreme 47
131.78
5 years 47
Extreme 47
145.65
10 years 47
Extreme 47
145.65
Manager TitleAgeSince
Chief Executive Officer 47 01/01/2026
Director of Finance/CFO 46 19/03/2021
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Chairman 68 30/07/2018
Director/Board Member 67 20/11/2009
Director/Board Member 47 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%-6.29% - - 27.61B
+1.39%+3.78%-17.43%-8.41% 180B
+1.21%+1.23%-9.38%-6.84% 107B
+0.41%+1.06%+7.16%+65.76% 60.29B
+0.67%-1.94%+27.88%+55.85% 50.19B
+1.64%+0.47%-14.25%-43.80% 43.08B
+2.45%-0.23% - - 32.77B
+0.93%-7.53%+25.71%-12.70% 23.1B
+2.02%+0.26%-5.23%-5.81% 20.86B
+3.90%-0.82%-13.10%+1.56% 19.5B
Average +1.91%-2.00%+0.17%+5.70% 59.54B
Weighted average by Cap. +1.73%-0.22%-5.33%+4.49%

Financials

2026 *2027 *
Net sales 5.22B 4.59B 4.27B 3.93B 7.37B 501B 7.47B 50.81B 19.85B 247B 19.61B 19.19B 855B 5.83B 5.12B 4.77B 4.38B 8.22B 559B 8.33B 56.68B 22.14B 276B 21.87B 21.4B 954B
Net income 959M 843M 785M 721M 1.35B 92.01B 1.37B 9.33B 3.65B 45.43B 3.6B 3.52B 157B 1.16B 1.02B 947M 870M 1.63B 111B 1.65B 11.26B 4.4B 54.8B 4.34B 4.25B 189B
Net Debt -429M -377M -351M -322M -605M -41.11B -613M -4.17B -1.63B -20.3B -1.61B -1.57B -70.17B -1.28B -1.13B -1.05B -962M -1.81B -123B -1.83B -12.46B -4.87B -60.64B -4.81B -4.7B -210B
Logo DexCom, Inc.
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 71.5% of net sales.
Employees
11,050
Date Price Change Volume
24/07/26 €62.60 +0.97% 0
23/07/26 €62.00 -2.82% 10
22/07/26 €63.80 -3.04% 0
21/07/26 €65.80 -2.08% 0
20/07/26 €67.20 +0.60% 60
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
71.54USD
Average target price
86.12USD
Spread / Average Target
+20.38%

Quarterly revenue - Rate of surprise